A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Aerie Pharmaceuticals logo

Aerie Pharmaceuticals

Status and phase

Phase 2


Open Angle Glaucoma
Ocular Hypertension


Drug: PG286 Ophthalmic Solution 0.5%
Drug: Travoprost Ophthalmic Solution 0.004%
Drug: AR-12286 Ophthalmic Solution 0.5%

Study type


Funder types




Details and patient eligibility


In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.


234 patients




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

Subject inclusion criteria

  1. 18 years of age or greater.
  2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
  3. Unmedicated (post-washout) IOP ≥ 22 mm Hg at 2 qualification visits (08:00 hr), 2-7 days apart. At second qualification visit, IOP >21 mmHg at 10:00 and 16:00 hrs.
  4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
  5. Able and willing to give signed informed consent and follow study instructions.

Subject exclusion criteria

Excluded from the study will be individuals with the following characteristics:

Ophthalmic (in either eye):

  1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.

  2. Intraocular pressure > 35 mm Hg, or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.

  3. Known hypersensitivity to any component of the formulation (benzalkonium chloride, zinc, etc.), travoprost, or to topical anesthetics.

  4. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).

  5. Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).

  6. Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.

  7. Evidence of ocular infection, inflammation, clinically significant blepharitis, conjunctivitis, or a history of herpes simplex keratitis at screening.

  8. Ocular medication of any kind within 30 days of screening, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after screening) or c) lubricating drops for dry eye (which may be used throughout the study).

  9. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (e.g., cup-disc ratio > 0.8).

  10. Central corneal thickness greater than 600 µm.

  11. Any abnormality preventing reliable applanation tonometry of either eye.


  12. Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.

  13. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.

  14. Participation in any investigational study within 30 days prior to screening.

  15. Changes of systemic medication within 30 days prior to screening, or anticipated during the study, that could have a substantial effect on IOP.

  16. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

234 participants in 3 patient groups

Experimental group
PG286 Ophthalmic Solution q.d. O.U.
Drug: PG286 Ophthalmic Solution 0.5%
AR-12286 Ophthalmic Solution 0.5%
Experimental group
AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
Drug: AR-12286 Ophthalmic Solution 0.5%
Travoprost 0.004%
Active Comparator group
Travoprost 0.004% q.d. O.U.
Drug: Travoprost Ophthalmic Solution 0.004%

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems